World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
90
Citations
32086
World Ranking
12145
National Ranking
6231

Miloslav Beran publication distribution in Medicine in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Medicine in 2026. The highlighted bar marks where Miloslav Beran sits on this spectrum.

101–120 publications: 5 scientists 121–140 publications: 26 scientists 141–160 publications: 73 scientists 161–180 publications: 155 scientists 181–200 publications: 230 scientists 201–220 publications: 363 scientists 221–240 publications: 487 scientists 241–260 publications: 545 scientists 261–280 publications: 722 scientists 281–300 publications: 768 scientists 301–320 publications: 834 scientists 321–340 publications: 895 scientists 341–360 publications: 922 scientists 361–380 publications: 838 scientists 381–400 publications: 861 scientists 401–420 publications: 918 scientists 421–440 publications: 806 scientists 441–460 publications: 771 scientists 461–480 publications: 751 scientists 481–500 publications: 713 scientists 501–520 publications: 617 scientists 521–540 publications: 611 scientists 541–560 publications: 537 scientists 561–580 publications: 504 scientists 581–600 publications: 509 scientists 601–620 publications: 396 scientists 621–640 publications: 386 scientists 641–660 publications: 371 scientists 661–680 publications: 340 scientists 681–700 publications: 336 scientists 701–720 publications: 307 scientists 721–740 publications: 259 scientists 741–760 publications: 230 scientists 761–780 publications: 228 scientists 781–800 publications: 217 scientists 801–820 publications: 204 scientists 821–840 publications: 186 scientists 841–860 publications: 177 scientists 861–880 publications: 155 scientists 881–900 publications: 139 scientists 901–920 publications: 145 scientists 921–940 publications: 116 scientists 941–960 publications: 133 scientists 961–980 publications: 91 scientists 981–1,000 publications: 96 scientists 1,001–1,020 publications: 77 scientists 1,021–1,040 publications: 70 scientists 1,041–1,060 publications: 63 scientists 1,061–1,080 publications: 77 scientists 1,081–1,100 publications: 49 scientists 1,101–1,120 publications: 54 scientists 1,121–1,140 publications: 49 scientists 1,141–1,160 publications: 51 scientists 1,161–1,180 publications: 35 scientists 1,181–1,200 publications: 39 scientists 1,201–1,220 publications: 26 scientists 1,221–1,240 publications: 37 scientists 1,241–1,260 publications: 36 scientists 1,261–1,280 publications: 27 scientists 1,281–1,300 publications: 32 scientists 1,301–1,320 publications: 28 scientists 1,321–1,340 publications: 17 scientists 1,341–1,360 publications: 30 scientists 1,361–1,380 publications: 28 scientists 1,381–1,400 publications: 17 scientists 1,401–1,420 publications: 21 scientists 1,421–1,440 publications: 15 scientists 1,441–1,460 publications: 12 scientists 1,461–1,480 publications: 12 scientists 1,481–1,500 publications: 18 scientists 1,501–1,520 publications: 14 scientists 1,521–1,540 publications: 17 scientists 1,541–1,560 publications: 15 scientists 1,561–1,580 publications: 6 scientists 1,581–1,600 publications: 2 scientists 1,601–1,620 publications: 12 scientists 1,621–1,640 publications: 11 scientists 1,641–1,660 publications: 8 scientists 1,661–1,680 publications: 5 scientists 1,681–1,700 publications: 5 scientists 1,701–1,720 publications: 10 scientists 1,721–1,740 publications: 12 scientists 1,741–1,760 publications: 14 scientists 1,761–1,780 publications: 6 scientists 1,781–1,795 publications: 5 scientists 1,796+ publications: 100 scientists
101 publications 1,796+

This scientist: 263 publications — 10th percentile

10% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 1,796 publications or more.

Miloslav Beran D-index placement in Medicine in 2026

The chart shows the D-index (discipline H-index) distribution of Medicine scientists ranked by Research.com in 2026. The highlighted bar marks where Miloslav Beran sits on this spectrum.

70–71 D-Index: 226 scientists 72–73 D-Index: 391 scientists 74–75 D-Index: 574 scientists 76–77 D-Index: 730 scientists 78–79 D-Index: 891 scientists 80–81 D-Index: 972 scientists 82–83 D-Index: 1,027 scientists 84–85 D-Index: 1,003 scientists 86–87 D-Index: 960 scientists 88–89 D-Index: 970 scientists 90–91 D-Index: 922 scientists 92–93 D-Index: 839 scientists 94–95 D-Index: 808 scientists 96–97 D-Index: 779 scientists 98–99 D-Index: 668 scientists 100–101 D-Index: 611 scientists 102–103 D-Index: 630 scientists 104–105 D-Index: 513 scientists 106–107 D-Index: 541 scientists 108–109 D-Index: 445 scientists 110–111 D-Index: 429 scientists 112–113 D-Index: 400 scientists 114–115 D-Index: 393 scientists 116–117 D-Index: 318 scientists 118–119 D-Index: 302 scientists 120–121 D-Index: 287 scientists 122–123 D-Index: 255 scientists 124–125 D-Index: 256 scientists 126–127 D-Index: 252 scientists 128–129 D-Index: 230 scientists 130–131 D-Index: 179 scientists 132–133 D-Index: 168 scientists 134–135 D-Index: 163 scientists 136–137 D-Index: 159 scientists 138–139 D-Index: 134 scientists 140–141 D-Index: 134 scientists 142–143 D-Index: 118 scientists 144–145 D-Index: 109 scientists 146–147 D-Index: 106 scientists 148–149 D-Index: 74 scientists 150–151 D-Index: 79 scientists 152–153 D-Index: 80 scientists 154–155 D-Index: 87 scientists 156–157 D-Index: 57 scientists 158–159 D-Index: 74 scientists 160–161 D-Index: 69 scientists 162–163 D-Index: 60 scientists 164–165 D-Index: 53 scientists 166–167 D-Index: 39 scientists 168–169 D-Index: 42 scientists 170–171 D-Index: 32 scientists 172–173 D-Index: 39 scientists 174–175 D-Index: 40 scientists 176–177 D-Index: 28 scientists 178–179 D-Index: 19 scientists 180–181 D-Index: 23 scientists 182–183 D-Index: 31 scientists 184–185 D-Index: 18 scientists 186–187 D-Index: 20 scientists 188–189 D-Index: 22 scientists 190–191 D-Index: 13 scientists 192–193 D-Index: 21 scientists 194–195 D-Index: 12 scientists 196–197 D-Index: 12 scientists 198–199 D-Index: 14 scientists 200–201 D-Index: 15 scientists 202–203 D-Index: 13 scientists 204–205 D-Index: 10 scientists 206–207 D-Index: 8 scientists 208–209 D-Index: 4 scientists 210–211 D-Index: 12 scientists 212–213 D-Index: 11 scientists 214–215 D-Index: 10 scientists 216 D-Index: 4 scientists 217+ D-Index: 98 scientists
70 D-Index 217+

This scientist: 90 D-Index — 41st percentile

41% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 217 D-Index or more.

Overview

Miloslav Beran is affiliated with The University of Texas MD Anderson Cancer Center in the United States. The institution is recognized for its medical research and cancer treatment focus, which provides a contextual backdrop for Beran's professional scope.

There are no recorded recent papers attributed to Miloslav Beran in the available data, nor are there listed frequent co-authors or venues of publication. This limits specific insights into the detailed research outputs or collaborative networks associated with the scientist.

The data does not include information about book publications, main scholarly fields, subfields of study, or principal topics of research. Additionally, there are no awards documented in relation to Beran's career, so any distinctions or recognitions remain unreported.

Given the lack of detailed publication and thematic data, this profile focuses on the known institutional affiliation, which may imply an orientation towards clinical or biomedical research activities related to cancer or related medical fields at MD Anderson. The absence of further research details suggests either unpublished or undisclosed work, or involvement in professional roles not captured by standard academic publication metrics.

Best Publications

  • Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

    Bruce D. Cheson;Peter L. Greenberg;John M. Bennett;Bob Lowenberg

  • Engraftment of Allogeneic Hematopoietic Progenitor Cells With Purine Analog-Containing Chemotherapy: Harnessing Graft-Versus-Leukemia Without Myeloablative Therapy

    Sergio Giralt;Elihu Estey;Maher Albitar;Koen Van Besien

  • Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation.

    Kelly Moran-Crusio;Linsey Reavie;Alan Shih;Omar Abdel-Wahab

  • Results of Treatment With Hyper-CVAD, a Dose-Intensive Regimen, in Adult Acute Lymphocytic Leukemia

    Hagop M Kantarjian;Susan O'Brien;Terry L. Smith;Jorge E Cortes

  • Report of an international working group to standardize response criteria for myelodysplastic syndromes

    B. D. Cheson;J. M. Bennett;Hagop M Kantarjian;A. Pinto

  • Genetic characterization of TET1, TET2, and TET3 alterations in myeloid malignancies

    Omar Abdel-Wahab;Ann Mullally;Cyrus Hedvat;Guillermo Garcia-Manero

  • Single-agent CEP-701, a novel FLT3 inhibitor, shows biologic and clinical activity in patients with relapsed or refractory acute myeloid leukemia

    B. Douglas Smith;Mark Levis;Mark Levis;Miloslav Beran;Miloslav Beran;Francis Giles;Francis Giles

  • Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia

    Hagop Kantarjian;Deborah Thomas;Susan O'Brien;Jorge Cortes

  • Treatment of Philadelphia chromosome–positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate

    Deborah A. Thomas;Stefan Faderl;Jorge Cortes;Susan O'Brien

  • Chemoimmunotherapy With Fludarabine, Cyclophosphamide, and Rituximab for Relapsed and Refractory Chronic Lymphocytic Leukemia

    William Wierda;Susan O'Brien;Sijin Wen;Stefan Faderl

  • Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy.

    M. J. Keating;S. O'Brien;S. Lerner;C. Koller

  • Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-α therapy

    Hagop M. Kantarjian;Terry L. Smith;Susan O'Brien;Miloslav Beran

  • Results of the Fludarabine and Cyclophosphamide Combination Regimen in Chronic Lymphocytic Leukemia

    Susan M. O’Brien;Hagop M. Kantarjian;Jorge Cortes;Miloslav Beran

  • Expression of the Wilms' tumor gene (WT1) in human leukemias.

    H Miwa;M Beran;G F Saunders

  • JAK2 mutation 1849G>T is rare in acute leukemias but can be found in CMML, Philadelphia chromosome–negative CML, and megakaryocytic leukemia

    Jaroslav Jelinek;Yasuhiro Oki;Vazganush Gharibyan;Vazganush Gharibyan;Vazganush Gharibyan;Carlos Bueso-Ramos

  • Prognostic nomogram and index for overall survival in previously untreated patients with chronic lymphocytic leukemia.

    William G. Wierda;Susan O'Brien;Xuemei Wang;Stefan Faderl

  • Prognostic factors and scoring systems in chronic myelomonocytic leukemia: a retrospective analysis of 213 patients

    Francesco Onida;Hagop M. Kantarjian;Terry L. Smith;Greg Ball

  • Results of Fludarabine and Prednisone Therapy in 264 Patients With Chronic Lymphocytic Leukemia With Multivariate Analysis-Derived Prognostic Model for Response to Treatment

    Susan O'Brien;Hagop Kantarjian;Miloslav Beran;Terry Smith

  • Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes: comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor.

    E Estey;P Thall;M Andreeff;M Beran

  • Long-term follow-up of patients with chronic lymphocytic leukemia treated with fludarabine as a single agent.

    Michael J. Keating;Susan O'Brien;Hagop Kantarjian;William Plunkett

Frequent Co-Authors

Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Susan O'Brien
Susan O'Brien University of California, Irvine
Elihu H. Estey
Elihu H. Estey University of Washington
Jorge E. Cortes
Jorge E. Cortes Augusta University
Francis J. Giles
Francis J. Giles Northwestern University
Michael J. Keating
Michael J. Keating The University of Texas MD Anderson Cancer Center
Srdan Verstovsek
Srdan Verstovsek The University of Texas MD Anderson Cancer Center
Stefan Faderl
Stefan Faderl The University of Texas MD Anderson Cancer Center
Sherry Pierce
Sherry Pierce The University of Texas MD Anderson Cancer Center
Deborah A. Thomas
Deborah A. Thomas The University of Texas MD Anderson Cancer Center

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing Medicine in the USA opens up a range of online degrees and career pathways that can expand your opportunities in the healthcare field. In addition to the traditional medical track, you can consider complementary degrees that are highly valued in today’s healthcare landscape.

For those interested in the business and management side of healthcare, the cheapest online master degree in healthcare administration provides essential leadership skills for running medical organizations. Nurses looking to advance their clinical expertise might explore the best online dnp programs to achieve a Doctor of Nursing Practice degree and increase their leadership potential.

Pharmacy remains a high-demand field, and earning a pharmacy degree online can prepare you for a career in medication management, research, or patient care. Additionally, managing health data is a critical part of today’s system, and accredited him programs (Health Information Management) can qualify you for specialized roles in medical records and informatics.

These flexible, affordable online programs offer alternative ways to build a rewarding healthcare career, whether you’re looking to specialize, lead, or support medical teams.

Best Scientists Citing Miloslav Beran

Recently Published Articles